Bristol-Myers Squibb Company

Biomarker Scientist-Immunoscience

Location
Princeton, NJ, US
Posted
Apr 12, 2018
Ref
R1504587
Required Education
Other
Position Type
Full time
The Biomarker Lead/Director for Orencia and Nulojix is responsible for developing and executing translational strategies for the Immunoscience pipeline with a particular focus on late-stage assets. The biomarker lead will act as a key interface with the Translational Medicine group.

The successful candidate will be responsible for integrating translational research and clinical development, developing a biomarker strategy in alignment with clinical development objectives, leading efforts for data generation, interpretation and communication to the development teams. The candidate will also be responsible for understanding the external research environment, partnering with discovery biology and other functions both internally and with external partners to coordinate the execution of deliverables.

-The Biomarker Lead/Director is responsible for:

- Developing and executing on translational strategies for the Orencia and Nulojix, as well as other assets within the immunoscience pipeline

- The successful candidate will be responsible for integrating translational research and clinical development, developing a biomarker strategy in alignment with clinical development objectives, leading efforts for data generation, interpretation and communication to the development teams.

- The candidate will also be responsible for understanding the external research environment, partnering with discovery biology and other functions both internally and with external partners to coordinate the execution of deliverables.

- Effectively engages with development teams and technical/scientific experts to define, revise and progress translational/biomarker plans

- Delivers high quality biomarker strategies for target engagement, pharmacodynamic endpoints and patient selection(where appropriate).

- Provides insight into novel ways to incorporate biomarkers into clinical designs to enable early understanding of emerging drug profiles.

- Effectively interfaces with the Translational Medicine group to obtain appropriate resources to deliver on biomarker goals.